AHA GUIDELINES Bundle (free trial)

ACCF/AHA Device-Based Therapy Guidelines

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/112380

Contents of this Issue

Navigation

Page 15 of 19

Diagnosis and Treatment Figure 2. Indications for Cardiac Resychronization Therapy Patient with cardiomyopathy on GDMT for ���3 mo or on GDMT and ���40 d after MI, or with implantation of pacing or defibrillation device for special indications LVEF ���35% Evaluate general health status Comorbidities and/ or frailty limit survival with good functional capacity to <1 y Continue GDMT without implanted device Acceptable noncardiac health Evaluate NYHA clinical status NYHA class I ������ LVEF ���30% ������ QRS ���150 ms ������ LBBB pattern ������ Ischemic cardiomyopathy ������ QRS ���150 ms ������ Non-LBBB pattern NYHA class II ������ LVEF ���35% ������ QRS ���150 ms ������ LBBB pattern ������ Sinus rhythm ������ LVEF ���35% ������ QRS 120-149 ms ������ LBBB pattern ������ Sinus rhythm ������ LVEF ���35% ������ QRS ���150 ms ������ Non-LBBB pattern ������ Sinus rhythm ������ QRS ���150 ms ������ Non-LBBB pattern NYHA class III & Ambulatory class IV ������ LVEF ���35% ������ QRS ���150 ms ������ LBBB pattern ������ Sinus rhythm ������ LVEF ���35% ������ QRS 120-149 ms ������ LBBB pattern ������ Sinus rhythm Special CRT Indications ������ Anticipated to require frequent ventricular pacing (>40%) ������ AF, if ventricular pacing is required and rate control will result in near 100% ventricular pacing with CRT ������ LVEF ���35% ������ QRS ���150 ms ������ Non-LBBB pattern ������ Sinus rhythm ������ LVEF ���35% ������ QRS 120-149 ms ������ Non-LBBB pattern ������ Sinus rhythm Colors correspond to the class of recommendations in the ACCF/AHA Table (pages 18-19). Benefit for NYHA class I and II patients has been shown in CRT-D trials, and while patients may not experience immediate symptomatic benefit, late remodeling may be avoided along with long-term HF consequences. There are no trials that support CRT-pacing (without ICD) in NYHA class I and II patients. Thus, it is anticipated these patients would receive CRT-D unless clinical reasons or personal wishes make CRT-pacing more appropriate. In patients who are NYHA class III and ambulatory class IV, CRT-D may be chosen but clinical reasons and personal wishes may make CRT-pacing appropriate to improve symptoms and quality of life when an ICD is not expected to produce meaningful benefit to survival. 14

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - ACCF/AHA Device-Based Therapy Guidelines